The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/foc.8.4.foc475

Schizophrenia is a serious mental illness responsible for tremendous morbidity and decreases in quality of life and productivity. It is the eighth leading cause of disability-associated life years lost (1) and accounts for nearly 1.1% of overall losses according to the World Health Organization (2). Although there are several treatments for schizophrenia, numerous individuals continue to experience the wide range of symptoms with which many patients present. Current medications target positive symptoms, i.e., hallucinations and delusions, but are not effective for negative symptoms, i.e., apathy, social dysfunction, and flat affect, or cognitive symptoms, such as deficits in executive function and working memory.